The role of p16-cyclin D/CDK-pRb pathway in endometrial cancer
Author Information
Author(s): Tsuda H, Yamamoto K, Inoue T, Uchiyama I, Umesaki N
Primary Institution: Osaka City General Hospital
Hypothesis
The study investigates the role of the p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrial carcinoma.
Conclusion
The expression of p16 and CDK4 may be an early event in the neoplastic transformation of endometrial cancer.
Supporting Evidence
- 20% of normal endometriums exhibited p16 nuclear staining.
- 50% of endometrial hyperplasias exhibited p16 nuclear staining.
- 82.9% of endometrial cancers exhibited p16 nuclear staining.
- p16 expression was significantly higher in endometrial cancers than in endometrial hyperplasias.
- 34.3% of endometrial cancers showed strong CDK4 staining.
- Strong CDK4 expression was higher in endometrial cancers than in endometrial hyperplasias.
- The abnormalities of the p16-cyclin D/CDK-pRb pathway were detected in 51.4% of endometrial cancers.
Takeaway
Researchers looked at how certain proteins are involved in the development of a type of cancer in the uterus, finding that changes in these proteins can happen early in the disease.
Methodology
The study analyzed p16 gene alteration and protein expression in normal endometriums, endometrial hyperplasias, and endometrial cancers.
Participant Demographics
The study included ten normal endometriums, 18 endometrial hyperplasias, and 35 endometrial cancers.
Statistical Information
P-Value
P = 0.0119, P = 0.0399, P = 0.0054
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website